Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pitfalls in the measurement of circulating vascular endothelial growth factor
Autore:
Jelkmann, W;
Indirizzi:
Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany Med Univ Lubeck Lubeck Germany D-23538 Physiol, D-23538 Lubeck, Germany
Titolo Testata:
CLINICAL CHEMISTRY
fascicolo: 4, volume: 47, anno: 2001,
pagine: 617 - 623
SICI:
0009-9147(200104)47:4<617:PITMOC>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
OVARIAN HYPERSTIMULATION SYNDROME; IN-VITRO FERTILIZATION; FACTOR VEGF; PERMEABILITY FACTOR; CANCER-PATIENTS; PLASMA-LEVELS; SERUM LEVELS; MYOCARDIAL-INFARCTION; LEVELS CORRELATE; FACTOR RECEPTOR;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
63
Recensione:
Indirizzi per estratti:
Indirizzo: Jelkmann, W Med Univ Lubeck, Inst Physiol, Ratzeburger Allee 160, D-23538 Lubeck, Germany Med Univ Lubeck Ratzeburger Allee 160 Lubeck Germany D-23538
Citazione:
W. Jelkmann, "Pitfalls in the measurement of circulating vascular endothelial growth factor", CLIN CHEM, 47(4), 2001, pp. 617-623

Abstract

Background: Vascular endothelial growth factor (VEGF) is a protein with antiapoptotic, mitogenic, and permeability-increasing activities specific forvascular endothelium. VEGF mRNA, which has five isoforms, is produced by nonmalignant cells in response to hypoxia and inflammation and by tumor cells in constitutively high concentrations. Because VEGF plays a crucial role in physiological and pathophysiological angiogenesis, measurements of circulating VEGF are of diagnostic and prognostic value, e.g., in cardiovascularfailures, inflammatory diseases, and malignancies. However, there are major quantitative differences in the published results. This review attempts to identify reasons for these disparities. Approach: The literature was reviewed through a Medline search covering 1995 to 2000. A selection of exemplary references had to be made for this perspective overview. Content: Data are included from studies on healthy humans, gynecological patients, and persons suffering from inflammatory or malignant diseases. Theresults indicate that competitive immunoassays detect the total amount of circulating VEGF, which enables observations regarding the increase in VEGFin pregnancy and preeclampsia to be made. In these cases, capture immunoassays utilizing neutralizing antibodies are insufficient because of an accompanying increase in VEGF-binding soluble receptors (sFlt-1). Measurements of circulating free VEGF are useful for study of malignant diseases, which are associated with both genetically and hypoxia-induced overproduction of VEGF. The VEGF isoform specificity of the antibodies is also critical because both VEGF(121) and VEGF(165) are secreted. It is important to consider that platelets and leukocytes release VEGF during blood clotting. Conclusions: Future efforts should concentrate on the balance between freeVEGF, total VEGF, and sFlt-1. Plasma, rather than serum, should be used for analysis. (C) 2001 American Association for Clinical Chemistry.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 14:05:37